Flaxseed Consumption on Biochemical and Quality of Life in Type 2 Diabetes
NCT ID: NCT06911060
Last Updated: 2025-08-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
46 participants
INTERVENTIONAL
2025-09-30
2026-05-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Does flaxseed supplementation given to T2DM patients for 12 weeks have an effect on biochemical parameters?
* Does flaxseed supplementation given to T2DM patients for 12 weeks have an effect on quality of life?
Researchers will compare patients with T2DM consume diet added flaxseed to a control group to see if flaxseed effect on biochemical parameters and quality of life.
Participants will:
* Complete the questionnaire, record the 3-day food consumption and be taken the anthropometric measurements at the beginning and end of the study.
* Take diet added 30 g ground flaxseed (intervention group) or only diet (control group) every day for 12 weeks.
* Visit the clinic once every 4 weeks for follow-up.
* Report the dietary adherence and gastrointestinal symptoms on a phone call once every week.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Does Flaxseed Supplementation Improve Glycemic Control in Individuals With Pre-diabetes?
NCT01698112
ACUTE EFFECT OF CONSUMPTION OF GROUND OR WHOLE FLAXSEEDS ON BLOOD GLUCOSE IN PEOPLE WITH TYPE 2 DIABETES
NCT06912542
The Potential Effects and Mechanisms of Flax Lignans on Type 2 Diabetes Mellitus
NCT00363233
Effect of Flaxseed as a Treatment for Adults With Type 2 Diabetes Mellitus in Mexico
NCT06683235
The Effect of Yogurt Enriched With Flaxseed on Cardiovascular Risk Factors in Type 2 Diabetic Patients
NCT02436369
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diet+Flaxseed
Diet will be planned to patients with T2DM as a part of their medical nutritional therapy. This group will take 30 g/d ground flaxseed within their diet.
Flaxseed
30 g/day for 12 weeks
Diet
Diet will be planned to patients with T2DM as a part of their medical nutrition therapy.
Diet
Diet will be planned to patients with T2DM as a part of their medical nutritional therapy.
Diet
Diet will be planned to patients with T2DM as a part of their medical nutrition therapy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Flaxseed
30 g/day for 12 weeks
Diet
Diet will be planned to patients with T2DM as a part of their medical nutrition therapy.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Being between the ages of 19-65
* Having a body mass index (BMI) between 20-35 kg/m2
* Using oral anti-diabetics and not using insulin
Exclusion Criteria
* High consumption of nuts, flaxseeds or sesame seeds (more than one serving per day)
* Food allergies or intolerances
* Malignancies
* Renal failure, liver, other endocrine or inflammatory disorders
* Use of lipid-lowering drugs
* Smoking and alcohol use
* Being pregnant or lactating
19 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ondokuz Mayıs University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
YASEMİN ERTAŞ ÖZTÜRK
Assist. Prof.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BAP08-2025-5797
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
BAP08-2025-5797
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.